Serum GFAP (sGFAP) and NfL (sNfL) have been shown to associate with MS disease severity [9, 16–20], although several studies have failed to demonstrate an association between longitudinal measurements and disability worsening over time [21–23]. This evidence concerns the gene GFAP and myeloid sarcoma.